RU2350348C2 - Лечение с применением ботулинического токсина - Google Patents
Лечение с применением ботулинического токсина Download PDFInfo
- Publication number
- RU2350348C2 RU2350348C2 RU2006123561/15A RU2006123561A RU2350348C2 RU 2350348 C2 RU2350348 C2 RU 2350348C2 RU 2006123561/15 A RU2006123561/15 A RU 2006123561/15A RU 2006123561 A RU2006123561 A RU 2006123561A RU 2350348 C2 RU2350348 C2 RU 2350348C2
- Authority
- RU
- Russia
- Prior art keywords
- bladder
- botulinum toxin
- balloon
- composition
- solid
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 231100000765 toxin Toxicity 0.000 title claims abstract description 22
- 239000003053 toxin Substances 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 24
- 210000003708 urethra Anatomy 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 4
- 108030001720 Bontoxilysin Proteins 0.000 claims description 89
- 229940053031 botulinum toxin Drugs 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 210000005070 sphincter Anatomy 0.000 claims description 10
- 239000008247 solid mixture Substances 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 208000005392 Spasm Diseases 0.000 claims description 7
- 206010046543 Urinary incontinence Diseases 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010020880 Hypertrophy Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010046555 Urinary retention Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000011514 reflex Effects 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000001272 neurogenic effect Effects 0.000 claims 2
- 230000027939 micturition Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 238000003892 spreading Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000009826 distribution Methods 0.000 abstract description 2
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 208000028484 Urethral disease Diseases 0.000 abstract 1
- 230000001148 spastic effect Effects 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000035515 penetration Effects 0.000 description 10
- 229940094657 botulinum toxin type a Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 241000193155 Clostridium botulinum Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000002581 neurotoxin Substances 0.000 description 4
- 231100000618 neurotoxin Toxicity 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010056948 Automatic bladder Diseases 0.000 description 3
- 208000003508 Botulism Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940098753 dysport Drugs 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010048994 Bladder spasm Diseases 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 108010069038 botulinum toxin type F Proteins 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 108010005730 R-SNARE Proteins Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 102000002215 Synaptobrevin Human genes 0.000 description 1
- 102000050389 Syntaxin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 108700017751 botulinum toxin type C Proteins 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- -1 glucocorticosteroids Chemical compound 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0328060.9 | 2003-12-04 | ||
| GBGB0328060.9A GB0328060D0 (en) | 2003-12-04 | 2003-12-04 | Botulinum toxin treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006123561A RU2006123561A (ru) | 2008-01-10 |
| RU2350348C2 true RU2350348C2 (ru) | 2009-03-27 |
Family
ID=29764527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006123561/15A RU2350348C2 (ru) | 2003-12-04 | 2004-11-12 | Лечение с применением ботулинического токсина |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070275110A1 (https=) |
| EP (1) | EP1691828B1 (https=) |
| JP (1) | JP5107578B2 (https=) |
| AT (1) | ATE475429T1 (https=) |
| CA (1) | CA2547618C (https=) |
| DE (1) | DE602004028403D1 (https=) |
| DK (1) | DK1691828T3 (https=) |
| ES (1) | ES2347151T3 (https=) |
| GB (1) | GB0328060D0 (https=) |
| PL (1) | PL1691828T3 (https=) |
| PT (1) | PT1691828E (https=) |
| RU (1) | RU2350348C2 (https=) |
| WO (1) | WO2005053733A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2605624C1 (ru) * | 2015-11-23 | 2016-12-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) | Способ лечения детрузорной гиперактивности |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
| ES2509872T3 (es) | 2005-03-03 | 2014-10-20 | Allergan, Inc. | Procedimientos para obtener una toxina clostrídica |
| US20090304747A1 (en) * | 2006-05-16 | 2009-12-10 | Mayo Foundation For Medical Education And Research | Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders |
| CA2678038C (en) | 2007-02-15 | 2016-10-11 | Allergan, Inc. | Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis |
| MX2010004502A (es) | 2007-10-23 | 2010-06-17 | Allergan Inc | Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas. |
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| WO2011089604A2 (en) | 2010-01-20 | 2011-07-28 | Theracoat Ltd | Material and method for treating internal cavities |
| US20130171122A1 (en) * | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
| RU2635466C2 (ru) * | 2012-04-08 | 2017-11-13 | Теракоат Лтд | Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия |
| JP2017532301A (ja) * | 2014-09-24 | 2017-11-02 | ウェルズリー ファーマスーティカルズ、エルエルシー | 膀胱痙攣を低減するための医薬製剤およびその使用の方法 |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| TWI810228B (zh) | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| CA3201129A1 (en) | 2020-12-11 | 2022-06-16 | Yulia HIONIDI | Material and method for treating cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US20030108597A1 (en) * | 2001-08-13 | 2003-06-12 | Chancellor Michael B. | Application of lipid vehicles and use for drug delivery |
| US20030211975A1 (en) * | 2000-05-01 | 2003-11-13 | Imarx Therapeutics Inc | Method and apparatus for vascular neuromuscular blockade |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236956A (en) * | 1988-11-04 | 1993-08-17 | Kabi Pharmacia Aktiebolag | Compounds for the treatment of urinary incontinence |
| SE8804003D0 (sv) * | 1988-11-04 | 1988-11-04 | Pharmacia Ab | Compounds for the treatment of urinary incontinence |
| JPH0564661A (ja) * | 1991-09-09 | 1993-03-19 | Olympus Optical Co Ltd | 体腔内挿入具 |
| US5749845A (en) | 1995-01-25 | 1998-05-12 | Iotek, Inc. | Delivering an agent to an organ |
| KR100544060B1 (ko) * | 1997-07-15 | 2006-01-23 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도 |
| US6630570B1 (en) * | 1999-04-09 | 2003-10-07 | Insitut für Diagnostikforschung GmbH | Short-chain peptide-dye conjugates as contrast media for optical diagnosis |
| DE19917713A1 (de) * | 1999-04-09 | 2000-10-19 | Diagnostikforschung Inst | Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik |
| US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US6638246B1 (en) * | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
| US20020099356A1 (en) * | 2001-01-19 | 2002-07-25 | Unger Evan C. | Transmembrane transport apparatus and method |
| DK1411978T3 (da) * | 2001-07-27 | 2009-01-05 | Univ Louisiana State | Botulinum-toksin ved behandlingen eller forebyggelsen af acne |
| WO2003061626A1 (en) * | 2002-01-18 | 2003-07-31 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| US20040067235A1 (en) * | 2002-07-29 | 2004-04-08 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
-
2003
- 2003-12-04 GB GBGB0328060.9A patent/GB0328060D0/en not_active Ceased
-
2004
- 2004-11-12 EP EP04798493A patent/EP1691828B1/en not_active Revoked
- 2004-11-12 ES ES04798493T patent/ES2347151T3/es not_active Expired - Lifetime
- 2004-11-12 DE DE602004028403T patent/DE602004028403D1/de not_active Expired - Lifetime
- 2004-11-12 AT AT04798493T patent/ATE475429T1/de active
- 2004-11-12 JP JP2006541996A patent/JP5107578B2/ja not_active Expired - Fee Related
- 2004-11-12 US US10/581,671 patent/US20070275110A1/en not_active Abandoned
- 2004-11-12 WO PCT/GB2004/004770 patent/WO2005053733A1/en not_active Ceased
- 2004-11-12 RU RU2006123561/15A patent/RU2350348C2/ru not_active IP Right Cessation
- 2004-11-12 PL PL04798493T patent/PL1691828T3/pl unknown
- 2004-11-12 CA CA2547618A patent/CA2547618C/en not_active Expired - Fee Related
- 2004-11-12 DK DK04798493.5T patent/DK1691828T3/da active
- 2004-11-12 PT PT04798493T patent/PT1691828E/pt unknown
-
2008
- 2008-05-29 US US12/155,104 patent/US8277822B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US20030211975A1 (en) * | 2000-05-01 | 2003-11-13 | Imarx Therapeutics Inc | Method and apparatus for vascular neuromuscular blockade |
| US20030108597A1 (en) * | 2001-08-13 | 2003-06-12 | Chancellor Michael B. | Application of lipid vehicles and use for drug delivery |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2605624C1 (ru) * | 2015-11-23 | 2016-12-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) | Способ лечения детрузорной гиперактивности |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1691828B1 (en) | 2010-07-28 |
| JP2007513127A (ja) | 2007-05-24 |
| WO2005053733A1 (en) | 2005-06-16 |
| US20070275110A1 (en) | 2007-11-29 |
| CA2547618C (en) | 2014-05-27 |
| DE602004028403D1 (de) | 2010-09-09 |
| PL1691828T3 (pl) | 2011-01-31 |
| JP5107578B2 (ja) | 2012-12-26 |
| DK1691828T3 (da) | 2010-11-01 |
| EP1691828A1 (en) | 2006-08-23 |
| ATE475429T1 (de) | 2010-08-15 |
| ES2347151T3 (es) | 2010-10-26 |
| RU2006123561A (ru) | 2008-01-10 |
| US20090028907A1 (en) | 2009-01-29 |
| GB0328060D0 (en) | 2004-01-07 |
| CA2547618A1 (en) | 2005-06-16 |
| PT1691828E (pt) | 2010-10-04 |
| US8277822B2 (en) | 2012-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8277822B2 (en) | Botulinum toxin treatment | |
| KR101041698B1 (ko) | 경피성 보툴리눔 독소 조성물 | |
| ES2281636T3 (es) | Uso de toxina botulinica para tratar enfermedades cardiovasculares. | |
| KR20030009431A (ko) | 신경독의 말초 투여를 통한 동통 처치 방법 | |
| JP2012116839A (ja) | 膵臓障害の処置方法 | |
| JP4602762B2 (ja) | 持続勃起症を処置するためのボツリヌス毒素 | |
| JP2003535117A (ja) | 神経毒インプラント | |
| JP2010519211A (ja) | 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用 | |
| ES2393217T3 (es) | Métodos para el tratamiento de una estenosis de uretra con una toxina botulínica | |
| KR101877273B1 (ko) | 보툴리눔 독소에 대한 마이크로 구조체 제형화 기술 | |
| Harper et al. | Botulinum toxin and its applications in the lower urinary tract. | |
| KR101211890B1 (ko) | 보툴리눔 독소를 사용한 튼살의 처치방법 | |
| CN111491659A (zh) | 用肉毒杆菌毒素治疗自主神经疾病 | |
| RU2741966C2 (ru) | Усовершенствованная схема инъекции в мочевой пузырь для введения ботулотоксинов | |
| US10792400B2 (en) | Microstructure formulation techniques for botulinum toxin | |
| CN114630672B (zh) | 肉毒杆菌毒素的微结构制备技术 | |
| CN109646673A (zh) | 肉毒杆菌毒素的微结构制剂技术 | |
| US10525111B2 (en) | Microstructure formulation techniques for botulinum toxin | |
| US7419675B2 (en) | Method for treating peritoneal adhesions | |
| CN101721683A (zh) | 人角质细胞生长因子1在制备治疗肛裂的药物中的应用 | |
| EP3470054B1 (en) | Microstructure formulation techniques for botulinum toxin | |
| HK40007558A (en) | Microstructure formulation techniques for botulinum toxin | |
| John et al. | Microbial Collagenases: Unveiling Therapeutic Horizons and Diverse Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201113 |